for Physical Chemists by Physical Chemists

Home Up Contents

Christine Prosser
Christine Prosser Paula Garcia John Comer Shenaz Nunhuck Darren Edwards Toni Llinās


Discovery PhysChem at UCB – AKAS and Beyond

Christine Prosser

It is a well-documented fact that as the R&D spend has increased year on year the number of new drugs reaching the market has decreased often as a result of undesirable properties, unrelated to potency or selectivity, which emerge late in the discovery process. In an attempt to reduce this costly late phase attrition pharmaceutical companies are introducing ADMET investigations in parallel with traditional biological assays as an early warning filter and to drive medicinal chemistry.

In the last year the acquisition of Celltech by UCB Pharma has created a major European based bio-pharma entity. This talk will highlight how the physical chemistry team at our Slough UK site is dedicated to developing robotic screens and now provides a cascade of physicochemical profiling assays for early discovery support.

Contact Information

For more information, please send an email to

You are visitor number

Send mail to with questions or comments about this web site.
Last modified: 28 April 2008